Private financing into life‑science tools and diagnostics firms declined materially in H2 2025, with total investment down about 20% year over year, reflecting macro uncertainty and tighter venture capital allocation. GenomeWeb and 360Dx deal tallies showed fewer transactions and lower aggregate capital for the tools segment. At the same time the FDA cleared and CLIA‑waived Diasorin’s LIAISON Nes four‑plex molecular point‑of‑care platform, signaling regulator and market interest in rapid, near‑patient testing. The divergence—falling private financings but continued regulatory activity—suggests consolidation and selective capital deployment in diagnostics.